Gilead Sciences

Gilead Breaks Ground on New US Manufacturing Hub

New Bay Area building marks significant progress as part of Gilead's $32 billion US investment.

Galapagos Intents to Split into Two Publicly Traded Entities

Galapagos, a biotechnology company headquartered in Belgium, plans to split into two entities: a newly formed company (name to be announced at a later date) that will focus on building a pipeline of innovative drugs through transformative transactions, and Galapagos, which will continue to develop its cell therapy manufacturing platform in oncology.

Gilead to Buy Liver Drugmaker CymaBay for $4.3 Billion

US biopharmaceutical company Gilead Sciences is to acquire CymaBay Therapeutics for $4.3 billion. Gilead offered to purchase all outstanding shares of CymaBay for $32.50 per share in cash.

Gilead and Compugen Strike Exclusive Deal for New Immunotherapy Program

Gilead has exclusive rights for the advancement and commercialization of anti-IL18 binding protein antibodies targeting various tumor types. Gilead commits to a significant deal, including a €55 million ($60 million) upfront payment and a €27 million ($30 million) milestone payment in the near term, with a total potential value of up to €775 million ($848 million).

Gilead Partners with Tentarix on Cancer and Inflammation Therapies

Gilead Sciences and Tentarix Biotherapeutics established three multi-year collaborations using Tentarix’s proprietary Tentacles platform to discover and develop multi-functional, conditional protein therapeutics for oncology and inflammatory diseases.

Gilead Buys Oxford Spin-out MiroBio

Gilead Sciences has agreed to acquire MiroBio, a privately held UK biotech focused on treating inflammatory diseases, for about $405 million in cash.

BioNTech Buying Cell Therapy Plant from Kite

Germany’s BioNTech, best known publicly for the Covid-19 vaccine Comirnaty it developed in partnership with US drugs giant Pfizer, has announced plans to buy a cell therapy R&D platform and clinical manufacturing plant from Gilead Sciences’ Kite Pharma subsidiary.

Innovation and Creativity in the Pharmaceutical Industry

The International Society for Pharmaceutical Engineering (ISPE) announced the 2021 Facility of the Year Awards (FOYA) Category Winners—including two winners of Special Recognition Awards for Operational Agility: Covid-19 Impact.

Drugs and Maybe Covid Vaccines Headed to India

As India’s Covid-19 infections soar and the death toll nears 200,000, wealthier countries – including the US, UK, Germany, France and Australia – are rushing supplies of oxygen, ventilators and protective gear to the subcontinent.

Gilead Takes Immunomedics for $21 Billion

Gilead Sciences is to acquire Immunomedics for approximately $21 billion. The deal, unanimously approved by both companies' boards of directors, will be funded by $15 billion in cash and $6 billion in new debt, and is expected to close during the fourth quarter of 2020.

FDA Extends EUA for Remdesivir in Covid Patients

The US Food and Drug Administration (FDA) has come under fire again as the federal health agency issued its third Emergency Use Authorization (EUA) for a Covid-19 treatment since the beginning of the pandemic. This extended the authorization for Gilead’s remdesivir, which it markets as Veklury.

Pfizer Teams up with Gilead to Make Remdesivir

After teaming up with Germany’s BioNTech to develop a vaccine for Covid-19, US drugs giant Pfizer is joining US Gilead Sciences on the therapeutic side. The biopharma company’s antiviral remdesivir is currently favored as a treatment for the novel coronavirus.

EU Inks Remdesivir Supply Deal with Gilead

The European Commission has signed a €63 million contract with Gilead Sciences to deliver batches of Veklury, Gilead’s name for the antiviral remdesivir, to the EU’s 27 member states as well as the UK, starting in early August.

EU Talks to Gilead About Remdesivir Supply

After it emerged last week that the US federal government had nailed down the lion’s share of the world’s supply of the antiviral remdesivir, Gilead Sciences’ new drug being touted as a promising treatment for Covid-19, the EU has held talks with the US drugmaker.

US Nabs Bulk of World Remdesivir Supply

As the global coronavirus pandemic shows no signs of abating, the US “America first” approach to preventing and treating Covid-19 has again provoked worldwide concern.

Dr. Reddy's Enters into a Licensing Agreement with Gilead for Remdesivir

AstraZeneca Said Weighing Gilead Merger

Gilead and Arcus in Oncology Pact

Gilead Licensing Remdesivir Production

Gilead Rescinds Orphan Drug Request

Gilead Boosts Immuno-oncology with Forty Seven

Gilead and Galapagos in Multi-billion Linkup

The Need for Innovation in Pharmaceutical Manufacturing

Gilead Nabs Roche Pharma Chief

Gilead HIV Pill Seen to Lower new Infections

Along the Acquisition Trail

New Rules For Pharma

Gilead to pay $12 Billion for Kite Pharma

Pharma Stocks Crash on Trump Pricing Hints

Best Pharma Brands

Gilead Sciences Faces Another Hepatitis C Lawsuit

Pfizer Takes Medivation for $14 billion

High Drug Prices Said Pressuring US Medicare

FDA Approves Pill for all Hepatitis C Forms

Alliance Works on Low Cost Cure for Hepatitis C